What Exeltis does

Exeltis USA, Inc. (formerly Everett Laboratories, founded 1971) is a US-based pharmaceutical subsidiary of the family-owned Insud Pharma Group, exclusively focused on women's health across the reproductive lifecycle — from fertility and contraception through pregnancy and menopause. The company markets a portfolio of FDA-approved prescription products including SLYND (an estrogen-free drospirenone-only oral contraceptive with a 24+4 dosing regimen), TWIRLA (a levonorgestrel/ethinyl estradiol transdermal contraceptive patch, acquired via Agile Therapeutics in June 2024), TYBLUME (a combination oral contraceptive), the Vitafol family of prenatal nutritional supplements (Vitafol Ultra, Gummies, One, Fe+, Nano, Strips, OB, OB+DHA), Pregnitude (a fertility supplement), and Nuvetest (a diagnostic). Products are supported by a clinical program that has enrolled approximately 3,000 women in 20 global studies covering about 20,000 female cycles of drug exposure, and the company is backed by Insud Pharma's 15 global production facilities and 10 R&D centers.

Exeltis operates a sales-led, B2B2C commercial model: a dedicated field sales organization engages OB/GYNs and women's health specialists who prescribe its products, and the company distributes through retail and specialty pharmacy channels nationwide. Revenue is generated through one-time prescription product sales at price points set by pharmacy, insurance coverage, and patient assistance programs rather than disclosed public pricing. The company maintains compliance with FDA regulations, OIG Guidance, the PhRMA Code, CCPA, and GDPR. Recent portfolio moves include the June 2024 acquisition of Agile Therapeutics, the January 2025 acquisition of Procare Health's women's health nutraceutical assets, a February 2026 licensing agreement with Dilafor, and a June 2026 divestiture of NUVESSA to Alembic Therapeutics, signaling active portfolio reshaping around its core contraceptive and prenatal franchises.

The US entity operates with approximately 101–250 employees from its Florham Park, NJ headquarters, while the broader Exeltis brand (part of Insud Pharma) employs nearly 6,000 people across more than 40 subsidiaries in 40+ countries with roughly 300 products in the global portfolio. Exeltis USA retains a focused, specialized go-to-market in the US women's health segment, supported by an entrepreneurially positioned leadership team including a Global Head with 12 years of cross-market experience at Insud Pharma.

Name

Exeltis

Legal name

Exeltis USA, Inc.

Website

https://exeltisusa.com

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

101–250 employees

Short description

Exeltis USA is a women's health pharmaceutical subsidiary of family-owned Insud Pharma, marketing FDA-approved contraceptives (SLYND, TWIRLA, TYBLUME), prenatal supplements (Vitafol family), and fertility products (Pregnitude) to OB/GYNs and patients via retail and specialty pharmacy distribution.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Women’s Health (OTC Gynecologic) (HLAIADAJ), Fertility & Ovulation Products (OTC) (CRABAIAK)

Keywords

• Women's health pharmaceuticals
• Prescription contraceptives
• Prenatal vitamins
• Transdermal drug delivery
• Fertility supplements

Headquarters

HQ city

Florham Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Revenue generated from selling prescription women's health medications including contraceptives (SLYND, TWIRLA, TYBLUME), prenatal vitamins (Vitafol family), and gynecological treatments (NUVESSA, Nuvetest). Products are FDA-approved prescription medications distributed through retail and specialty pharmacy channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Exeltis develops, manufactures, and commercializes FDA-approved prescription pharmaceutical products exclusively focused on women's health. Its portfolio spans the reproductive lifecycle and includes oral contraceptives (SLYND, TYBLUME), a transdermal contraceptive patch (TWIRLA), a vaginal gel for bacterial vaginosis (NUVESSA), the Vitafol family of prescription and over-the-counter prenatal nutritional supplements, fertility supplements (Pregnitude), and diagnostic products (Nuvetest). Products are sold in the United States through retail and specialty pharmacy distribution and prescribed by OB/GYNs and women's health specialists engaged via a dedicated field sales force.

Product overview

Exeltis is an independent, family-owned women's healthcare company that offers an extensive portfolio of pharmaceutical products across multiple categories. The company's core offerings include prescription birth control options (Slynd, Twirla, Tyblume), treatments for bacterial vaginosis (Nuvessa), prenatal nutritional supplements (Vitafol family including Vitafol Ultra, Vitafol Gummies, Vitafol One, Vitafol Fe+, Vitafol Nano, Vitafol Strips, Vitafol OB, Vitafol OB+ DHA), fertility supplements (Pregnitude), diagnostic products (Nuvetest), and additional women's health products (Blue's Away). The portfolio addresses women's health needs at key stages of life including fertility, contraception, pregnancy, and menopause. Exeltis is part of the Insud Pharma group, with operations spanning over 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Slynd: Estrogen-free progestin-only birth control pill (POP) with drospirenone
• Twirla
• Tyblume
• Vitafol
• Nuvessa
• Nuvetest
• Blue's Away
• Pregnitude

Products and services

• SLYND (drospirenone) Estrogen-free, progestin-only prescription oral contraceptive (POP) for women of reproductive age, offering a unique 24 active + 4 placebo dosing regimen and a 24-hour missed pill window.
• TWIRLA (levonorgestrel/ethinyl estradiol) Transdermal birth control patch delivering levonorgestrel and ethinyl estradiol through the skin for women seeking a non-daily hormonal contraceptive option.
• TYBLUME (ethinyl estradiol and levonorgestrel) Combination prescription oral contraceptive containing ethinyl estradiol and levonorgestrel, marketed for women of reproductive age to prevent pregnancy.
• Nuvetest Women's health diagnostic product related to vaginal health testing, available through the Exeltis women's health product portfolio.
• Vitafol Ultra Prenatal supplement in the Vitafol family formulated to support nutritional needs during pregnancy.
• Vitafol Gummies Gummy-formulated prenatal supplement in the Vitafol family, providing an alternative delivery form to traditional pill-based prenatal vitamins.
• Vitafol One Once-daily prenatal supplement in the Vitafol family designed for comprehensive prenatal nutritional support.
• Vitafol Fe+ Iron-fortified prescription prenatal supplement in the Vitafol family for pregnant women requiring additional iron.
• Vitafol Nano Nano-formulated prenatal supplement in the Vitafol family with smaller particle size intended to enhance nutrient absorption.
• Vitafol Strips Strip-formulated prenatal supplement in the Vitafol family designed for convenient oral administration as an alternative to capsules or tablets.
• Vitafol OB Prescription prenatal supplement in the Vitafol family with a comprehensive prenatal nutritional formula.
• Vitafol OB+ DHA Prenatal supplement in the Vitafol family fortified with DHA (docosahexaenoic acid) to support fetal brain and eye development.
• Blue's Away Women's health product in the Exeltis portfolio; specific indication and category not detailed in the available source material.
• Pregnitude Fertility supplement designed to support reproductive health for women trying to conceive.

Quantifiable outcome

• 20 global clinical studies including phases I, II and III, totaling about 20,000 female cycles of drug exposure for SLYND development
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and moderate.

• Alembic TherapeuticsminorChannel Partner/ Reseller/ Distributor · 1 June 2026Alembic Therapeutics acquired NUVESSA (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc. in June 2026. Alembic assumes full responsibility for commercialization and distribution across the United States.
• DilaformoderateStrategic or Co-development Partner · 1 February 2026Dilafor signed a licensing term sheet with Exeltis. Dilafor also secured a US patent during this period. The partnership involves Exeltis licensing terms with the Swedish pharmaceutical company.
• Procare HealthmoderateStrategic or Co-development Partner · 1 January 2025Exeltis (part of Insud Pharma) acquired women's health nutraceutical assets from Procare Health in January 2025, expanding its fertility supplements portfolio.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Agile Therapeutics: Developer of the TWIRLA contraceptive patch that was acquired by Exeltis in 2024 — directly comparable as a women's health transdermal contraceptive peer now operating within the Exeltis platform.
• Noven Pharmaceuticals: Specialist in transdermal drug delivery (patches) — directly comparable to Exeltis on TWIRLA transdermal patch technology and women's health patch-based delivery.
• TherapeuticsMD: US-listed women's health company focused on prescription hormones, contraception, and menopause — a comparable specialty pharma commercializing branded women's health products through OB/GYN channels.
• Organon & Co. Public women's health specialty pharma spun out of Merck in 2021 with a portfolio spanning contraception, fertility, and menopause — the most direct large-scale comparable to Exeltis's women-health focus and prescriber-driven model.
• HRA Pharma: European women's health specialty pharma (now part of Perrigo) with focus on contraception, emergency contraception, and menopause — closely comparable business model and prescriber base to Exeltis.

Broad incumbents

• AbbVie / Allergan Aesthetics: Through the Allergan acquisition, AbbVie holds major women's health assets (e.g., Lo Loestrin Fe) — a broad incumbent peer competing on contraceptive prescriptions, formulary access, and lifecycle management.
• Bayer (Women's Health / Pharma): Major incumbent with leading hormonal contraceptive franchises (Yaz, Yasmin, Mirena) — overlapping significantly with Exeltis's contraceptive portfolio and exerting significant competitive and pricing pressure.
• Pfizer (Women's Health): Large diversified pharma with broad women's health and contraceptive offerings; competes directly with Exeltis on combined oral contraceptives and brings materially larger commercial and R&D resources.

Emerging players

• Amneal Pharmaceuticals: US specialty and generics pharma with growing women's health presence including prenatal vitamins and select branded women's health products — a partial overlap with Exeltis's Vitafol franchise.
• Lupin Pharmaceuticals: India-headquartered specialty/generics pharma with US women's health portfolio (oral contraceptives, prenatal vitamins) — a relevant emerging competitor in prescription women's health and prenatal supplements.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ExeltisUSA
• Instagraminstagram.com/exeltisusa
• LinkedInlinkedin.com/company/exeltis
• Xx.com/exeltis

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exeltis